S-Adenosylmethionine/ Silybin

Verify with FDA CVM →

14 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
14
Total Reports
1
Deaths Reported
710.0%
Death Rate

Active Ingredients

S-Adenosylmethionine/ Silybin

Administration Routes

Oral

Species Affected

Dog 13
Cat 1

Most Affected Breeds

Terrier - Yorkshire 2
Pekingese 1
Spitz - German Pomeranian 1
Crossbred Canine/dog 1
Terrier - Tibetan 1
Maltese 1
Terrier - Jack Russell 1
Shepherd Dog - Australian 1
Retriever - Labrador 1
Pug 1

Most Reported Reactions

Other abnormal test result NOS 4
Emesis 4
Elevated alanine aminotransferase (ALT) 3
Lethargy (see also Central nervous system depression in 'Neurological') 3
Elevated serum alkaline phosphatase (SAP) 3
Diarrhoea 2
Tense abdomen 2
Decreased appetite 2
Elevated liver enzymes 2
Elevated aspartate aminotransferase (AST) 2
Elevated bile acids 1
Hyperpigmentation 1

Outcome Breakdown

Ongoing
9 (64.3%)
Recovered/Normal
4 (28.6%)
Euthanized
1 (7.1%)

Data Summary

Metric Value
Total adverse event reports 14
Reports involving death 1
Case-fatality rate (reported events) 710.0%
Distinct species in reports 2
Distinct breeds in reports 13
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

S-Adenosylmethionine/ Silybin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 14 adverse event reports referencing S-Adenosylmethionine/ Silybin, including 1 reports in which the animal died — a 710.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: S-Adenosylmethionine/ Silybin. Reported administration route is Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in S-Adenosylmethionine/ Silybin reports are Dog (13 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Terrier - Yorkshire (2), Pekingese (1), Spitz - German Pomeranian (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with S-Adenosylmethionine/ Silybin are Other abnormal test result NOS (4), Emesis (4), Elevated alanine aminotransferase (ALT) (3), Lethargy (see also Central nervous system depression in 'Neurological') (3). Of the 14 reports with a coded outcome, Ongoing is the leading category at 64.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on S-Adenosylmethionine/ Silybin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial